RAPT Therapeutics, Inc. (RAPT) EPS (Weighted Average and Diluted) (2021 - 2024)
RAPT Therapeutics (RAPT) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with $12.61 as the latest value for Q4 2024.
- Quarterly EPS (Weighted Average and Diluted) rose 1656.79% to $12.61 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.34 through Dec 2024, up 176.72% year-over-year, with the annual reading at -$3.19 for FY2024, 4.59% down from the prior year.
- EPS (Weighted Average and Diluted) hit $12.61 in Q4 2024 for RAPT Therapeutics, up from -$3.79 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $12.61 in Q4 2024 to a low of -$5.69 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.34 across 4 years, with a median of -$0.66 in 2023.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 1656.79% in 2024; the steepest drop was 762.12% in 2024.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then dropped by 6.56% to -$0.65 in 2022, then decreased by 24.62% to -$0.81 in 2023, then skyrocketed by 1656.79% to $12.61 in 2024.
- Business Quant data shows EPS (Weighted Average and Diluted) for RAPT at $12.61 in Q4 2024, -$3.79 in Q3 2024, and -$5.69 in Q2 2024.